DE60105418D1 - Serinprotease-inhibitoren - Google Patents

Serinprotease-inhibitoren

Info

Publication number
DE60105418D1
DE60105418D1 DE60105418T DE60105418T DE60105418D1 DE 60105418 D1 DE60105418 D1 DE 60105418D1 DE 60105418 T DE60105418 T DE 60105418T DE 60105418 T DE60105418 T DE 60105418T DE 60105418 D1 DE60105418 D1 DE 60105418D1
Authority
DE
Germany
Prior art keywords
serine protease
protease inhibitors
inhibitors
factor
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60105418T
Other languages
English (en)
Other versions
DE60105418T2 (de
Inventor
John Walter Liebeschuetz
Christopher William Murray
Stephen Clinton Young
Nicholas Paul Camp
Stuart Donald Jones
William Alexander Wylie
Joseph Masters
Robert Wiley
Martin Sheehan
Birenbaum Engel
Morgan Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2000/002302 external-priority patent/WO2000076971A2/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE60105418D1 publication Critical patent/DE60105418D1/de
Publication of DE60105418T2 publication Critical patent/DE60105418T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60105418T 2000-06-13 2001-06-12 Serinprotease-inhibitoren Expired - Fee Related DE60105418T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2000/002302 WO2000076971A2 (en) 1999-06-14 2000-06-13 Serine protease inhibitors
WOPCT/GB00/02302 2000-06-13
GB0030303 2000-12-13
GBGB0030303.2A GB0030303D0 (en) 2000-12-13 2000-12-13 Compounds
PCT/GB2001/002541 WO2001096296A1 (en) 2000-06-13 2001-06-12 Serine protease inhibitors

Publications (2)

Publication Number Publication Date
DE60105418D1 true DE60105418D1 (de) 2004-10-14
DE60105418T2 DE60105418T2 (de) 2005-09-15

Family

ID=9904936

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60105418T Expired - Fee Related DE60105418T2 (de) 2000-06-13 2001-06-12 Serinprotease-inhibitoren

Country Status (10)

Country Link
US (2) US6878725B2 (de)
EP (1) EP1289950B1 (de)
JP (1) JP2004503532A (de)
AT (1) ATE275544T1 (de)
AU (1) AU2001264065A1 (de)
CA (1) CA2411798A1 (de)
DE (1) DE60105418T2 (de)
ES (1) ES2228874T3 (de)
GB (1) GB0030303D0 (de)
WO (1) WO2001096296A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6407701A (en) * 2000-06-13 2001-12-24 Tularik Ltd Serine protease inhibitors
AU2002322396A1 (en) 2001-07-26 2003-02-17 Eli Lilly And Company 1-glycinyl-4 (methylpiperidin-4-yl) piperazines and -piperridines as factor xa antagonists
MY130373A (en) * 2001-10-29 2007-06-29 Malesci Sas Linear basic compounds having nk-2 antagonist activity and formulations thereof
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
PL373066A1 (en) 2002-04-01 2005-08-08 Eli Lilly And Company Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor xa
JP4980928B2 (ja) * 2004-12-24 2012-07-18 プロシディオン・リミテッド Ｇタンパク質共役受容体（ｇｐｒ１１６）作動薬および肥満および糖尿病治療のためのその使用
WO2009134666A1 (en) 2008-04-29 2009-11-05 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
WO2009137338A1 (en) * 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
JP5507567B2 (ja) 2008-09-26 2014-05-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体拮抗薬としてのアザインダゾール化合物
WO2010065799A2 (en) * 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
KR20120069710A (ko) * 2009-09-08 2012-06-28 교린 세이야꾸 가부시키 가이샤 ４?(５?메틸피리딘?２?일아미노)피페리딘?１?카복실산 유도체의 제조방법
KR20120087923A (ko) 2009-10-21 2012-08-07 베링거 인겔하임 인터내셔날 게엠베하 Ｃｃｒ１ 수용체 길항제로서의 인다졸 및 피라졸로피리딘 화합물
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
BR112012013582A2 (pt) * 2009-12-08 2016-07-05 Boehringer Ingelheim Int processo para síntese de intermediários úteis para a produção de compostos de indazol e azaindazol substituídos
US8871786B2 (en) 2010-04-30 2014-10-28 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as CCR1 receptor antagonists
CN102464654B (zh) * 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
JP5684406B2 (ja) 2010-12-23 2015-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのピラゾロピペリジン化合物
MX2016013049A (es) 2014-04-04 2017-04-27 X-Rx Inc Inhibidores de autotaxina espirociclicos sustituidos.
WO2015175171A1 (en) * 2014-04-23 2015-11-19 X-Rx Discovery, Inc. Substituted n-(2-(amino)-2-oxoethyl)benzamide inhibitors of autotaxin and their preparation and use in the treatment of lpa-dependent or lpa-mediated diseases
KR102099608B1 (ko) * 2017-11-17 2020-04-10 성균관대학교산학협력단 퀴놀린-8-일메탄아민, 이의 제조방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
US20220348563A1 (en) * 2019-09-13 2022-11-03 Dana-Farber Cancer Institute, Inc. Kdm inhibitors and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
IE902295A1 (en) 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
CA2200163A1 (en) 1996-03-22 1997-09-22 Michael Robert Wiley Antithrombotic diamides
AU3496297A (en) 1996-06-25 1998-01-14 Eli Lilly And Company Anticoagulant agents
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
AU8269398A (en) 1997-06-26 1999-01-19 Eli Lilly And Company Antithrombotic agents
DE69830504T2 (de) 1997-06-26 2006-03-16 Eli Lilly And Co., Indianapolis Antithrombotische mitteln
IL133621A0 (en) 1997-06-26 2001-04-30 Lilly Co Eli Antithrombotic agents
US6417200B1 (en) 1997-06-26 2002-07-09 Eli Lilly And Company Antithrombotic agents
WO2000077027A2 (en) 1999-06-14 2000-12-21 Tularik Limited Serine protease inhibitors
EP1009758B1 (de) * 1997-08-29 2005-06-01 Tularik Limited Meta-benzamidinderivate als serinprotease-inhibitoren
US6740682B2 (en) * 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
CN1302292A (zh) * 1998-03-19 2001-07-04 味之素株式会社 氨基异喹啉衍生物
ATE272633T1 (de) 1998-12-23 2004-08-15 Lilly Co Eli Aromatische amiden
JP2002533453A (ja) 1998-12-23 2002-10-08 イーライ・リリー・アンド・カンパニー Ｘａ因子のインヒビターとしてのヘテロ芳香族アミド
EP1140881B1 (de) 1998-12-23 2006-05-17 Eli Lilly And Company Antithrombotische amide
ES2217879T3 (es) 1998-12-24 2004-11-01 Eli Lilly And Company Amidas heterociclicas.
WO2000071507A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
AU5723500A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
GB9929552D0 (en) * 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
ES2248084T3 (es) 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
US7074934B2 (en) * 2000-06-13 2006-07-11 Tularik Limited Serine protease inhibitors
GB0030306D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds

Also Published As

Publication number Publication date
DE60105418T2 (de) 2005-09-15
ATE275544T1 (de) 2004-09-15
US20040242656A1 (en) 2004-12-02
GB0030303D0 (en) 2001-01-24
EP1289950A1 (de) 2003-03-12
US20030078438A1 (en) 2003-04-24
CA2411798A1 (en) 2001-12-20
WO2001096296A1 (en) 2001-12-20
JP2004503532A (ja) 2004-02-05
AU2001264065A1 (en) 2001-12-24
EP1289950B1 (de) 2004-09-08
ES2228874T3 (es) 2005-04-16
US6878725B2 (en) 2005-04-12

Similar Documents

Publication Publication Date Title
MXPA02011411A (es) Inhibidores de proteasa de serina.
ATE304532T1 (de) Inhibitoren von serin proteasen
DE60105418D1 (de) Serinprotease-inhibitoren
ATE303988T1 (de) Inhibitoren von serin proteasen
WO2000076970A3 (en) Serine protease inhibitors
GB0030306D0 (en) Compounds
DE60126978D1 (de) Inhibitoren von serin proteasen
DE60202669D1 (de) 6-phenylbenzonaphthyidine
ATE348803T1 (de) Tryptase-inhibitoren
ATE364037T1 (de) Tryptasehemmer
ATE344795T1 (de) Inhibitoren von serinproteasen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee